Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care
CompletedOBSERVATIONAL
Enrollment
1,000
Participants
Timeline
Start Date
June 3, 2020
Primary Completion Date
July 18, 2024
Study Completion Date
July 18, 2024
Conditions
MDS (Myelodysplastic Syndrome)
Trial Locations (2)
10060
Elena Crisà, Candiolo
20089
IRCCS Humanitas Research Hospital, Rozzano
All Listed Sponsors
lead
Fondazione Italiana Sindromi Mielodisplastiche-ETS
OTHER
NCT04212390 - Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care | Biotech Hunter | Biotech Hunter